SB-249553

DB05285ExperimentalSmall molecule

SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. It is also under by GlaxoSmithKline to treat melanoma and lung cancer.

Primary indication
lung cancer/melanomaCurator reviewed
Code names
SB-249553

Which companies are running trials of SB-249553, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In